Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The company now has a substantially larger market awaiting us, and while its commercialisation strategy for ColoSTAT has changed, this strategy has been successful. Wait, has Rhythm received TGA approval? Yes and no - it's a long…

ByNick SundichFebruary 17, 2026

Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?

Ansell Shrugs Off Tariffs with Strong Pricing Power Ansell (ASX: ANN) reported half-year results on Monday that told a story most ASX investors weren't expecting. Revenue barely moved, up just 0.7% to US$1.03 billion, yet adjusted net profit surged 18% to US$95.7 million. The gap between those two numbers reveals something important: this is a…

ByUjjwal MaheshwariFebruary 17, 2026

Australian Clinical Labs (ASX:ACL) The Statutory Hit Spooked Investors

Australian Clinical Labs fell 10% today after revenue went slightly backwards, even though underlying profit improved. The key nuance is that management deliberately walked away from low margin collection centres and contracts. That decision can pull revenue down in the short term, but it should lift margins and improve the quality of earnings over time. The sharper…

ByCharlie YouldenFebruary 16, 2026

Why ASX Healthcare Stocks Are Crashing- and Which One Looks Like a Buy

ASX healthcare stocks are crashing- which one is worth buying now? Three of Australia's most premium ASX healthcare stocks have been crushed in the same week. CSL (ASX: CSL) has fallen to its lowest price since 2018, plunging 15% in a single week to touch a low of A$150. Pro Medicus (ASX: PME) has plunged…

ByUjjwal MaheshwariFebruary 14, 2026

Cochlear (ASX:COH) Down 16% on a Softer Half, What the Market Is Really Pricing

Cochlear had a softer start to its half yearly result, with sales of A$1.1 billion down around 1%. The bigger issue for investors was underlying net profit, which appears to have been the key driver behind the 16% drawdown and the broader selling pressure. Net cash remained solid at A$173 million, although it was down…

ByCharlie YouldenFebruary 13, 2026

Pro Medicus (ASX:PME) Down 16% on a Great Result, Here’s Why

A Premium Multiple Leaves No Room for “Good” Pro Medicus fell 16% despite what, on the surface, looked like an exceptional half yearly result. A lot of investors will be asking the obvious question: how can a company print a strong result and still get sold off that hard? The core principle here is asset pricing.…

ByCharlie YouldenFebruary 12, 2026

A Blood Test Instead of a Colonoscopy? Rhythm Biosciences (ASX:RHY) Takes Its First Commercial Step

Rhythm Biosciences Starts ColoSTAT Pilot, Revenue Still Unclear Rhythm Biosciences (ASX: RHY) just hit a milestone the market has been waiting for, enrolling its first doctor in the ColoSTAT Access Program, a small pilot program that will test its blood-based bowel cancer screening product in real clinical settings for the first time. The share price…

ByUjjwal MaheshwariFebruary 12, 2026

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon following a tenure of nearly 3 years. It was clear that something had to give, but this is still a shock as it occurred a day before company results and resulted in McKenzies' tenure lasting…

ByNick SundichFebruary 11, 2026

This company just made an IND submission to the US FDA, here’s why its a big step!

Imagion Biosystems (ASX:IBX) just made a IND submission. This is a big deal for the company, and we thought it would be the perfect time to explain to investors just what this means. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"] [/sg_popup] Here's what you need to know about…

ByNick SundichFebruary 10, 2026

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the company's clinical outlook and follows a strong rally that began in early December after Immutep signed a landmark licensing deal with Dr Reddy's Laboratories. What…

ByUjjwal MaheshwariFebruary 7, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?

Australian Clinical Labs (ASX:ACL) The Statutory Hit Spooked Investors

Why ASX Healthcare Stocks Are Crashing- and Which One Looks Like a Buy

Cochlear (ASX:COH) Down 16% on a Softer Half, What the Market Is Really Pricing

Pro Medicus (ASX:PME) Down 16% on a Great Result, Here’s Why

A Blood Test Instead of a Colonoscopy? Rhythm Biosciences (ASX:RHY) Takes Its First Commercial Step

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

This company just made an IND submission to the US FDA, here’s why its a big step!

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here